163 related articles for article (PubMed ID: 12077739)
1. Normalizing glycated albumin reduces increased urinary collagen IV and prevents renal insufficiency in diabetic db/db mice.
Cohen MP; Hud E; Shea E; Shearman CW
Metabolism; 2002 Jul; 51(7):901-5. PubMed ID: 12077739
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting albumin glycation ameliorates diabetic nephropathy in the db/db mouse.
Cohen MP; Masson N; Hud E; Ziyadeh F; Han DC; Clements RS
Exp Nephrol; 2000; 8(3):135-43. PubMed ID: 10810230
[TBL] [Abstract][Full Text] [Related]
3. Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists. A novel treatment strategy.
Cohen MP; Sharma K; Jin Y; Hud E; Wu VY; Tomaszewski J; Ziyadeh FN
J Clin Invest; 1995 May; 95(5):2338-45. PubMed ID: 7738197
[TBL] [Abstract][Full Text] [Related]
4. Evidence linking glycated albumin to altered glomerular nephrin and VEGF expression, proteinuria, and diabetic nephropathy.
Cohen MP; Chen S; Ziyadeh FN; Shea E; Hud EA; Lautenslager GT; Shearman CW
Kidney Int; 2005 Oct; 68(4):1554-61. PubMed ID: 16164632
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting albumin glycation in vivo ameliorates glomerular overexpression of TGF-beta1.
Cohen MP; Ziyadeh FN; Hong SW; Shearman CW; Hud E; Lautenslager GT; Iglesias-de la Cruz MC; Chen S
Kidney Int; 2002 Jun; 61(6):2025-32. PubMed ID: 12028443
[TBL] [Abstract][Full Text] [Related]
6. Increased urinary type IV collagen marks the development of glomerular pathology in diabetic d/db mice.
Cohen MP; Lautenslager GT; Shearman CW
Metabolism; 2001 Dec; 50(12):1435-40. PubMed ID: 11735089
[TBL] [Abstract][Full Text] [Related]
7. Prevention of decline in renal function in the diabetic db/db mouse.
Cohen MP; Clements RS; Cohen JA; Shearman CW
Diabetologia; 1996 Mar; 39(3):270-4. PubMed ID: 8721771
[TBL] [Abstract][Full Text] [Related]
8. Amelioration of diabetic nephropathy by treatment with monoclonal antibodies against glycated albumin.
Cohen MP; Hud E; Wu VY
Kidney Int; 1994 Jun; 45(6):1673-9. PubMed ID: 7933815
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting albumin glycation attenuates dysregulation of VEGFR-1 and collagen IV subchain production and the development of renal insufficiency.
Cohen MP; Lautenslager GT; Hud E; Shea E; Wang A; Chen S; Shearman CW
Am J Physiol Renal Physiol; 2007 Feb; 292(2):F789-95. PubMed ID: 17018845
[TBL] [Abstract][Full Text] [Related]
10. Increased collagen IV excretion in diabetes. A marker of compromised filtration function.
Cohen MP; Lautenslager GT; Shearman CW
Diabetes Care; 2001 May; 24(5):914-8. PubMed ID: 11347754
[TBL] [Abstract][Full Text] [Related]
11. Effect of renal function on serum concentration of 1,5-anhydroglucitol in type 2 diabetic patients in chronic kidney disease stages I-III: A comparative study with HbA1c and glycated albumin.
Hasslacher C; Kulozik F
J Diabetes; 2016 Sep; 8(5):712-9. PubMed ID: 26615054
[TBL] [Abstract][Full Text] [Related]
12. SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice.
Sugaru E; Nakagawa T; Ono-Kishino M; Nagamine J; Tokunaga T; Kitoh M; Hume WE; Nagata R; Taiji M
Am J Physiol Renal Physiol; 2006 Apr; 290(4):F813-20. PubMed ID: 16278277
[TBL] [Abstract][Full Text] [Related]
13. Evolution of renal function abnormalities in the db/db mouse that parallels the development of human diabetic nephropathy.
Cohen MP; Clements RS; Hud E; Cohen JA; Ziyadeh FN
Exp Nephrol; 1996; 4(3):166-71. PubMed ID: 8773479
[TBL] [Abstract][Full Text] [Related]
14. Deletion of Smad3 prevents renal fibrosis and inflammation in type 2 diabetic nephropathy.
Xu BH; Sheng J; You YK; Huang XR; Ma RCW; Wang Q; Lan HY
Metabolism; 2020 Feb; 103():154013. PubMed ID: 31734275
[TBL] [Abstract][Full Text] [Related]
15. Accumulation of glycated albumin in end-stage renal failure: evidence for the principle of "physiological microalbuminuria".
Donnelly SM
Am J Kidney Dis; 1996 Jul; 28(1):62-6. PubMed ID: 8712223
[TBL] [Abstract][Full Text] [Related]
16. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody.
Flyvbjerg A; Dagnaes-Hansen F; De Vriese AS; Schrijvers BF; Tilton RG; Rasch R
Diabetes; 2002 Oct; 51(10):3090-4. PubMed ID: 12351452
[TBL] [Abstract][Full Text] [Related]
17. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice.
Ziyadeh FN; Hoffman BB; Han DC; Iglesias-De La Cruz MC; Hong SW; Isono M; Chen S; McGowan TA; Sharma K
Proc Natl Acad Sci U S A; 2000 Jul; 97(14):8015-20. PubMed ID: 10859350
[TBL] [Abstract][Full Text] [Related]
18.
Yoon JJ; Park JH; Kim HJ; Jin HG; Kim HY; Ahn YM; Kim YC; Lee HS; Lee YJ; Kang DG
Nutrients; 2019 Mar; 11(3):. PubMed ID: 30841605
[TBL] [Abstract][Full Text] [Related]
19. Preferential excretion of glycated albumin in C57BL-Ks-J mice: effects of diabetes.
Kowluru A; Kowluru RA
Experientia; 1992 May; 48(5):486-8. PubMed ID: 1601114
[TBL] [Abstract][Full Text] [Related]
20. Renal handling of glycated albumin in non-insulin-dependent diabetes mellitus with nephropathy.
Cha T; Tahara Y; Yamato E; Yoneda H; Ikegami H; Noma Y; Shima K; Ogihara T
Diabetes Res Clin Pract; 1991 Jul; 12(3):149-56. PubMed ID: 1889345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
